Market Cap 367.78M
Revenue (ttm) 14.20M
Net Income (ttm) -49.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -349.23%
Debt to Equity Ratio -2.69
Volume 4,415,100
Avg Vol 1,144,924
Day's Range N/A - N/A
Shares Out 82.65M
Stochastic %K 83%
Beta 0.58
Analysts Strong Sell
Price Target $10.55

Company Profile

Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs...

Industry: Biotechnology
Sector: Healthcare
Phone: 984 884 6030
Website: opusgtx.com
Address:
8 Davis Drive, Suite 220, Durham, United States
BOUDIN420
BOUDIN420 Sep. 3 at 11:34 PM
0 · Reply
Abarone1980
Abarone1980 Sep. 3 at 5:14 PM
$IRD loveeeee
0 · Reply
Abarone1980
Abarone1980 Sep. 3 at 5:14 PM
0 · Reply
signaljumper
signaljumper Sep. 3 at 3:16 PM
$IRD 5.75 is the next bigger resistance to Break
0 · Reply
markb0305
markb0305 Sep. 3 at 2:03 PM
$IRD if it hits $10 I’ll buy everyone in here a McChicken
0 · Reply
signaljumper
signaljumper Sep. 3 at 6:42 AM
$IRD https://finviz.com/news/387867/opus-genetics-to-present-opgx-best1-cohort-1-clinical-data-in-investor-webcast-and-at-upcoming-leading-ophthalmology-conferences
0 · Reply
LewisDaKat
LewisDaKat Sep. 2 at 10:30 PM
$IRD Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences https://marketwirenews.com/stock/ird/news/opus-genetics-to-present-opgx-best1-cohort-1-clinica-8968835821001023.html?utm_source=stocktwits
0 · Reply
JussieLivermore
JussieLivermore Sep. 2 at 9:07 PM
$IRD Do we hit $5.81 before data is released?
1 · Reply
TheAliAbdul
TheAliAbdul Sep. 2 at 8:35 PM
$IRD 9th September is huge for us now
0 · Reply
Abarone1980
Abarone1980 Sep. 2 at 7:21 PM
0 · Reply
Latest News on IRD
Opus Genetics Registration statement: Registration filing

Aug 7, 2026, 8:00 AM EDT - 27 days ago

Opus Genetics Registration statement: Registration filing


Opus Genetics files $300M mixed securities shelf

2026-08-07T10:25:56.000Z - 27 days ago

Opus Genetics files $300M mixed securities shelf


Opus Genetics reports Q2 EPS (14c), consensus (16c)

2026-08-06T11:20:54.000Z - 4 weeks ago

Opus Genetics reports Q2 EPS (14c), consensus (16c)


Opus Genetics Earnings release: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 4 weeks ago

Opus Genetics Earnings release: Q2 2026


Opus Genetics Quarterly report: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 4 weeks ago

Opus Genetics Quarterly report: Q2 2026


Opus Genetics enrolls last patient in OPGx-LCA5 trial

2026-08-03T11:50:12.000Z - 4 weeks ago

Opus Genetics enrolls last patient in OPGx-LCA5 trial


Opus Genetics initiated with a Buy at TD Cowen

2026-07-29T09:35:19.000Z - 5 weeks ago

Opus Genetics initiated with a Buy at TD Cowen


Opus Genetics announces FDA alignment on OPGx-LCA5 trial

2026-07-06T11:10:18.000Z - 1 month ago

Opus Genetics announces FDA alignment on OPGx-LCA5 trial


Opus Genetics initiated with an Outperform at RBC Capital

2026-06-23T11:14:14.000Z - 2 months ago

Opus Genetics initiated with an Outperform at RBC Capital


Opus Genetics assumed with a Buy at Chardan

2026-06-18T00:25:07.000Z - 2 months ago

Opus Genetics assumed with a Buy at Chardan


Opus Genetics Transcript: R&D Day 2026

Jun 16, 2026, 10:00 AM EDT - 2 months ago

Opus Genetics Transcript: R&D Day 2026


Opus Genetics Slides: FY 2026

Jun 16, 2026, 10:00 AM EDT - 2 months ago

Opus Genetics Slides: FY 2026


Opus Genetics management to meet with BTIG

2026-06-12T17:40:25.000Z - 2 months ago

Opus Genetics management to meet with BTIG


Opus Genetics Registration statement: Registration filing

Jun 5, 2026, 8:00 AM EDT - 3 months ago

Opus Genetics Registration statement: Registration filing


Opus Genetics initiated with a Buy at Guggenheim

2026-06-04T10:16:57.000Z - 3 months ago

Opus Genetics initiated with a Buy at Guggenheim


Opus Genetics management to meet with Citizens

2026-06-03T17:55:11.000Z - 3 months ago

Opus Genetics management to meet with Citizens


Opus Genetics Slides: Investor presentation

May 30, 2026, 7:00 AM EDT - 3 months ago

Opus Genetics Slides: Investor presentation


Opus Genetics initiated with an Outperform at Leerink

2026-05-21T10:33:45.000Z - 3 months ago

Opus Genetics initiated with an Outperform at Leerink


Opus Genetics initiated with an Outperform at Leerink

2026-05-21T10:17:22.000Z - 3 months ago

Opus Genetics initiated with an Outperform at Leerink


Opus Genetics Slides: Corporate presentation

May 17, 2026, 7:00 AM EDT - 3 months ago

Opus Genetics Slides: Corporate presentation


Opus Genetics price target lowered to $11 from $12 at Citizens

2026-05-13T09:57:18.000Z - 3 months ago

Opus Genetics price target lowered to $11 from $12 at Citizens


Opus Genetics Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 3 months ago

Opus Genetics Quarterly report: Q1 2026


Opus Genetics Registration statement: Registration filing

Apr 21, 2026, 8:00 AM EDT - 4 months ago

Opus Genetics Registration statement: Registration filing


Opus Genetics Proxy statement: Proxy filing

Mar 23, 2026, 8:00 AM EDT - 5 months ago

Opus Genetics Proxy statement: Proxy filing


Opus Genetics Slides: Corporate presentation

Mar 16, 2026, 7:11 PM EDT - 5 months ago

Opus Genetics Slides: Corporate presentation


Opus Genetics Registration statement: Registration filing

Mar 13, 2026, 8:00 AM EDT - 5 months ago

Opus Genetics Registration statement: Registration filing


Opus Genetics Proxy statement: Proxy filing

Mar 12, 2026, 8:00 AM EDT - 5 months ago

Opus Genetics Proxy statement: Proxy filing


Opus Genetics Earnings release: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 5 months ago

Opus Genetics Earnings release: Q4 2025


Opus Genetics Annual report: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 5 months ago

Opus Genetics Annual report: Q4 2025


Opus Genetics Announces $25 Million Private Placement

Feb 13, 2026, 7:30 AM EST - 6 months ago

Opus Genetics Announces $25 Million Private Placement


Opus Genetics to Participate in Upcoming Investment Conferences

Nov 20, 2025, 8:00 AM EST - 9 months ago

Opus Genetics to Participate in Upcoming Investment Conferences


Opus Genetics Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 9 months ago

Opus Genetics Earnings release: Q3 2025


Opus Genetics Quarterly report: Q3 2025

Nov 12, 2025, 7:00 AM EST - 9 months ago

Opus Genetics Quarterly report: Q3 2025


Opus Genetics Announces $23 Million Registered Direct Offering

Nov 6, 2025, 7:00 AM EST - 10 months ago

Opus Genetics Announces $23 Million Registered Direct Offering


Opus Genetics Transcript: Study result

Sep 30, 2025, 8:30 AM EDT - 11 months ago

Opus Genetics Transcript: Study result


Opus Genetics Press release: Study result

Sep 30, 2025, 8:30 AM EDT - 11 months ago

Opus Genetics Press release: Study result


Opus Genetics Slides: Study result

Sep 30, 2025, 8:30 AM EDT - 11 months ago

Opus Genetics Slides: Study result


Opus Genetics Appoints Rob Gagnon as Chief Financial Officer

Sep 2, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics Appoints Rob Gagnon as Chief Financial Officer


Opus Genetics Earnings release: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 1 year ago

Opus Genetics Earnings release: Q2 2025


Opus Genetics Quarterly report: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 1 year ago

Opus Genetics Quarterly report: Q2 2025


Opus Genetics Transcript: Investor update

Jun 26, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics Transcript: Investor update


Opus Genetics Press release: Investor update

Jun 26, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics Press release: Investor update


BOUDIN420
BOUDIN420 Sep. 3 at 11:34 PM
0 · Reply
Abarone1980
Abarone1980 Sep. 3 at 5:14 PM
$IRD loveeeee
0 · Reply
Abarone1980
Abarone1980 Sep. 3 at 5:14 PM
0 · Reply
signaljumper
signaljumper Sep. 3 at 3:16 PM
$IRD 5.75 is the next bigger resistance to Break
0 · Reply
markb0305
markb0305 Sep. 3 at 2:03 PM
$IRD if it hits $10 I’ll buy everyone in here a McChicken
0 · Reply
signaljumper
signaljumper Sep. 3 at 6:42 AM
$IRD https://finviz.com/news/387867/opus-genetics-to-present-opgx-best1-cohort-1-clinical-data-in-investor-webcast-and-at-upcoming-leading-ophthalmology-conferences
0 · Reply
LewisDaKat
LewisDaKat Sep. 2 at 10:30 PM
$IRD Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences https://marketwirenews.com/stock/ird/news/opus-genetics-to-present-opgx-best1-cohort-1-clinica-8968835821001023.html?utm_source=stocktwits
0 · Reply
JussieLivermore
JussieLivermore Sep. 2 at 9:07 PM
$IRD Do we hit $5.81 before data is released?
1 · Reply
TheAliAbdul
TheAliAbdul Sep. 2 at 8:35 PM
$IRD 9th September is huge for us now
0 · Reply
Abarone1980
Abarone1980 Sep. 2 at 7:21 PM
0 · Reply
Just_playin_around45
Just_playin_around45 Sep. 2 at 6:31 PM
$IRD 😁
0 · Reply
Ron_Burn
Ron_Burn Sep. 2 at 4:27 PM
$IRD nice gap up, good for a swing
0 · Reply
prismmarketview
prismmarketview Sep. 2 at 4:11 PM
PRISM Mid-Day Movers: MedTech and New Energy are Today’s Leaders bioAffinity Technologies (NASDAQ: $BIAF ) is up sharply again today, gaining roughly 56% intraday, following yesterday's ~46% surge tied to news that CyPath® Lung will be positioned for post-treatment surveillance of lung cancer survivors, expanding the test's commercial use beyond initial screening. Montauk Renewables, Inc. (NASDAQ: $MNTK ) is up roughly 17% today, trading near $2.07 on volume well above its daily average, a notable pop for the landfill-methane-to-renewable-energy company, though no fresh company-specific catalyst has surfaced yet. Other Notable Movers: Ocuphire Pharma, Inc. ($IRD) up 13% FiscalNote ($NOTE) up 13% BioXcel Therapeutics, Inc. ($BTAI ) down -20% https://prismmarketview.com/prism-mid-day-movers-medtech-and-new-energy-are-todays-leaders-2/
0 · Reply
BiotechButterflies
BiotechButterflies Sep. 2 at 2:33 PM
$IRD .. count down to 9-sept data readout begins.... a gem of a company.... fingers crossed for the 9th Sept....
0 · Reply
TNNStockAnalysisNews
TNNStockAnalysisNews Sep. 2 at 2:16 AM
Today’s Top Gaining Stocks (Sep 1, 2026): $GPRO — Rocketed as Much as 82.61% on a Surprise Merger $BIAF — Surged Up to 68.4% on Expanded Product Use Case $FRVO — Jumped 28.41% on a 396-Megawatt Google Power Deal $ORA — Rose 5.19% on the Same Geothermal Tailwind $IRD — Gained 5.9% Ahead of a Defining Clinical Data Readout https://truthsandnews.com/markets/top-gaining-stocks-today-sep-1-2026-biggest-movers
0 · Reply
Nikko288
Nikko288 Sep. 1 at 6:57 PM
$IRD Yesterday and today, we were misled by news bots; they were mistaken in claiming that the IRD clinical results would be released today, September 1st. Even so, I managed to make a profit trading. Next week is the decisive one. Everyone stay tuned
0 · Reply
bondia
bondia Sep. 1 at 2:21 PM
$IRD waiting too for results from lynx 3
0 · Reply
Just_playin_around45
Just_playin_around45 Aug. 31 at 5:35 PM
$IRD who is adding with the draw down before data release🙋🏼‍♂️. Love it
0 · Reply
Invescent
Invescent Aug. 31 at 1:49 PM
$IRD Catalyst setup Price: ~$3.69 September 2026: OPGx-BEST1 Cohort 1 clinical data expected October 17, 2026: FDA PDUFA for phentolamine ophthalmic solution 0.75% in presbyopia Phase 3 VEGA-3: 27.2% hit primary vision endpoint vs 11.5% placebo p<0.0001 Short float: ~15% Days to cover: ~15 Two catalysts ahead + elevated short interest. $IRD on watch.
0 · Reply
BOUDIN420
BOUDIN420 Aug. 28 at 6:46 PM
$IRD thanks for the Gap fill before September top line data and October 17th PDUFA
0 · Reply
JussieLivermore
JussieLivermore Aug. 28 at 1:53 PM
$IRD $3.40 - $3.80 is where I am adding back shares.
0 · Reply
GladEator
GladEator Aug. 26 at 8:28 PM
$IRD Talk about a pile of . ....
1 · Reply